NCT05391555View on ClinicalTrials.gov

Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

June 3, 2023

Study Completion Date

June 3, 2023

Conditions
Opioid ToxicityPupillary MiosisRespiratory Depression
Interventions
DRUG

Remifentanil Hydrochloride

Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes.

DEVICE

Pupillometry measurement

Pupillary measurements were taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.

Trial Locations (1)

94143

University of California San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER